Asphelia Pharmaceuticals

Asphelia Pharmaceuticals, Inc. operates as a clinical-stage company focused on developing therapies for immune-mediated diseases. It provides treatments for inflammatory bowel disease and other immune and inflammatory conditions, including multiple sclerosis and asthma. The company also offers ASP1002, a helminth-based technology for treating Crohn's disease; ASP2002, an oral compound taken once daily that targets integrins for the treatment of immune and inflammatory diseases; and ASP1001, a topical formulation of iodinated contrast agents for treating allergic conditions.